1-甲基-2-(甲硫基)-1H-咪唑-5-甲醛 | 105956-24-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-2-(甲硫基)-1H-咪唑-5-甲醛
• 英文名称: 1-methyl-2-(methylthio)-1H-imidazole-5-carbaldehyde
• 英文别名: 1-methyl-2-methylthio-1H-imidazole-5-carbaldehyde；1-methyl-2-methylthio-5-formyl-1H-imidazole；3-methyl-2-methylsulfanyl-3H-imidazole-4-carbaldehyde；1H-1-methyl-2-(methylthio)imidazole-5-carboxaldehyde；3-methyl-2-methylsulfanylimidazole-4-carbaldehyde
• CAS: 105956-24-9
• 化学式: C₆H₈N₂OS
• 分子量: 156.208
• InChiKey: MAYWCNRSPBECQE-UHFFFAOYSA-N

物化性质

• 熔点：
  63-64 °C
• 沸点：
  327.6±34.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  60.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-甲基-2-(甲硫基)-1H-咪唑-5-甲醛 生成 3-Methyl-2-methylsulfonylimidazole-4-carbaldehyde
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  5-羟甲基-1-甲基-2-甲硫基-1H-咪唑 在 manganese(IV) oxide 作用下， 以 氯仿 为溶剂， 生成 1-甲基-2-(甲硫基)-1H-咪唑-5-甲醛
  参考文献：
  名称：

  取代的吡咯并[2,3- d ]咪唑的合成

  摘要：

  从容易获得的5-羟甲基-2-巯基-1-甲基咪唑（1）开始，制备取代的吡咯并[2，3- d ]咪唑。

  DOI：

  10.1002/jhet.5570340233

文献信息

• [EN] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES<br/>[FR] 3-'4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL-N-ARYL-BENZAMIDES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE CYTOKINES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2005090333A1

  公开（公告）日：2005-09-29

  Disclosed compounds of formula (I), which inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

  公开的化合物式(I)，可以抑制与炎症过程有关的细胞因子的产生，因此可用于治疗涉及炎症的疾病和病理状况，如慢性炎症性疾病。还公开了制备这些化合物的方法以及包含这些化合物的药物组合物。
• Azaindoles
  申请人：——

  公开号：US20040009983A1

  公开（公告）日：2004-01-15

  The invention is directed to compositions containing physiologically active compounds of general formula (I): 1 wherein R 1 is aryl or heteroaryl; R 2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, —Z 1 R 8 , —C(═O)—NY 3 Y 4 , —CO 2 R 8 , —NY 3 Y 4 , —N(R 6 )—C(═O)—R 7 , —N(R 6 )—C(═O)—NY 3 Y 4 , —N(R 6 )—C(═O)—OR 7 , —N(R 6 )—SO 2 —R 7 , —N(R 6 )—SO 2 —NY 3 Y 4 and one or more halogen a toms ; R 3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, —C(═O)—OR 5 or —C(═O)—NY 3 Y; and X 1 represents N, CH, C-halo, C—CN, C—R 7 , C—NY 3 Y 4 , C—OH, C—Z 2 R 7 , C—C(═O)—OR 5 , C—C(═O)—NY 3 Y 4 , C—N(R 8 )—C(═O)—R 7 , C—SO 2 —NY 3 Y 4 , C—N(R 8 )—SO 2 —R 7 , C-alkenyl, C-alkynyl or C—NO 2 ; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases.

  这项发明涉及含有一般式（I）中生理活性化合物的组合物：其中R1为芳基或杂芳基；R2代表氢、酰基、氰基、卤素、可选择地由氰基、杂芳基、杂环烷基、—Z1R8、—C（═O）—NY3Y4、—CO2R8、—NY3Y4、—N(R6)—C（═O）—R7、—N(R6)—C（═O）—NY3Y4、—N(R6)—C（═O）—OR7、—N(R6)—SO2—R7、—N(R6)—SO2—NY3Y4和一个或多个卤原子取代的较低烯基或较低烷基；R3代表氢、芳基、氰基、卤素、杂芳基、较低烷基、—C（═O）—OR5或—C（═O）—NY3Y；X1代表N、CH、C-卤素、C—CN、C—R7、C—NY3Y4、C—OH、C—Z2R7、C—C（═O）—OR5、C—C（═O）—NY3Y4、C—N(R8)—C（═O）—R7、C—SO2—NY3Y4、C—N(R8)—SO2—R7、C-烯基、C-炔基或C—NO2；以及它们的前药、这些化合物及其前药的药学上可接受的盐和溶剂，以及在一般式（I）范围内的新化合物。这些化合物和组合物具有有价值的药物特性，特别是抑制蛋白激酶的能力。
• Synthesis and antiproliferative activity evaluation of imidazole-based indeno[1,2-b]quinoline-9,11-dione derivatives
  作者：Hasti Sarkarzadeh、Ramin Miri、Omidreza Firuzi、Mohsen Amini、Nima Razzaghi-Asl、Najmeh Edraki、Abbas Shafiee

  DOI：10.1007/s12272-013-0032-7

  日期：2013.4

  A series of new imidazole substituted indeno[1,2-b]quinoline-9,11-dione derivatives were synthesized and evaluated for their antiproliferative effects on HeLa, LS180, MCF-7 and Jurkat human cancer cell lines. Antiproliferative effects were evaluated using MTT assay. Prepared compounds exhibited weak to good antiproliferative activity in evaluated cell lines. Prepared compounds were more potent in Jurkat cell line when compared to LS180, HeLa and MCF-7 cell lines. Compounds 29 (IC16 = 0.7 μM) and 31 (IC16 = 1.7 μM) and 33 (IC16 = 1.7 μM) were found to be the most potent molecules on Jurkat cell lines. Moreover; it was found that some of the tested compounds bearing imidazole-2-yl moiety on the C11-position of dihydropyridine ring exhibited superior antiproliferative activity in comparison to cis-platin especially in Jurkat cell line (compounds 29, 31, and 33). It seemed that the introduction of electron-withdrawing groups on the imidazole ring enhanced the antiproliferative potential of these compounds (compounds 27, 29 and 31). The results of this study proposed that some of the imidazole substituted indeno[1,2-b]quinoline-9,11-dione compounds may act as efficient anticancer agents in vitro, emphasizing their potential role as a source for rational design of potent antiproliferative agents.

  一系列新的咪唑取代的印烯[1,2-b]喹啉-9,11-二酮衍生物被合成并评估了其对人类癌细胞系HeLa、LS180、MCF-7和Jurkat的抗增殖效果。抗增殖效果通过MTT法进行评估。所制备的化合物在评估的细胞系中表现出从弱到良好的抗增殖活性。在与LS180、HeLa和MCF-7细胞系相比时，所制备的化合物在Jurkat细胞系中的效能更强。化合物29（IC16 = 0.7 μM）、31（IC16 = 1.7 μM）和33（IC16 = 1.7 μM）被发现是Jurkat细胞系中最有效的分子。此外，发现一些在双氢吡啶环C11位点上带有咪唑-2-基的测试化合物，其抗增殖活性优于顺铂，特别是在Jurkat细胞系中（化合物29、31和33）。似乎在咪唑环上引入电子吸引基团增强了这些化合物的抗增殖潜力（化合物27、29和31）。本研究结果表明，一些咪唑取代的印烯[1,2-b]喹啉-9,11-二酮化合物可能作为有效的抗癌剂在体外发挥作用，强调了它们作为有效抗增殖剂的合理设计来源的潜在角色。
• 4,5-Disubstituted <i>N</i> -Methylimidazoles as Versatile Building Blocks for Defined Side-Chain Introduction
  作者：Daniel Przybyla、Udo Nubbemeyer

  DOI：10.1002/ejoc.201601384

  日期：2017.1.18

  Two strategies for the synthesis of fungerin and its derivatives have been developed. An orthogonally protected key 4,5‐di(hydroxymethyl)imidazole intermediate gave fungerin analogues in five steps. Furthermore 5‐(2‐sulfonylethyl)‐4‐bromoimidazole gave several target imidazoles after two additional steps with complete regioselectivity.

  已经开发了两种合成真菌素及其衍生物的策略。正交保护的关键4,5-二（羟甲基）咪唑中间体通过五个步骤提供了fungerin类似物。此外，在另外两个步骤后，5-（2-磺酰基乙基）-4-溴咪唑具有完全的区域选择性，从而生成了几种目标咪唑。
• Synthesis and calcium channel antagonist activity of nifedipine analogues with methylthioimidazole substituent
  作者：A Foroumadi、N Analuie、M Rezvanipour、G Sepehri、H Najafipour、H Sepehri、K Javanmardi、F Esmaeeli

  DOI：10.1016/s0014-827x(01)01191-0

  日期：2002.3

  Various diester analogues of nifedipine, in which the orthonitrophenyl group at position 4 is replaced by 1-methyl-2-methylthio-5-imidazolyl substituent, were synthesized and evaluated as calcium channel antagonists on guinea-pig ileal smooth muscle. Nifedipine was used as standard. Comparison of the activities of symmetrical esters (3a-e) indicate that increasing the length of alkyl chain in C3 and

  合成了硝苯地平的各种二酯类似物，其中第4位的邻硝基苯基被1-甲基-2-甲硫基-5-咪唑基取代基取代，并被用作豚鼠回肠平滑肌上的钙通道拮抗剂。硝苯地平用作标准品。比较对称酯（3a-e）的活性表明，增加C3和C5酯取代基中烷基链的长度会增加拮抗剂的活性，正丙基酯是优选的（IC50 = 2.66 x 10（-9）M） 。在不对称系列（6a-g）中，发现在碱性二氢吡啶结构的C3和C5位置具有乙酯和正丁酯的化合物6g最具活性（IC50 = 1.32 x 10（-9）M）。

表征谱图